首页> 外文期刊>Disease models & mechanisms: DMM >Akkermansia muciniphila promotes type H vessel formation and bone fracture healing by reducing gut permeability and inflammation
【24h】

Akkermansia muciniphila promotes type H vessel formation and bone fracture healing by reducing gut permeability and inflammation

机译:Akkermansia粘蛋白通过降低肠道渗透率和炎症而促进H型血管形成和骨折愈合

获取原文
           

摘要

ABSTRACT Improving revascularization is one of the major measures in fracture treatment. Moderate local inflammation triggers angiogenesis, whereas systemic inflammation hampers angiogenesis. Previous studies showed that Akkermansia muciniphila , a gut probiotic, ameliorates systemic inflammation by tightening the intestinal barrier. In this study, fractured mice intragastrically administrated with A. muciniphila were found to display better fracture healing than mice treated with vehicle. Notably, more preosteclasts positive for platelet-derived growth factor-BB (PDGF-BB) were induced by A. muciniphila at 2?weeks post fracture, coinciding with increased formation of type H vessels, a specific vessel subtype that couples angiogenesis and osteogenesis, and can be stimulated by PDGF-BB. Moreover, A. muciniphila treatment significantly reduced gut permeability and inflammation at the early stage. Dextran sulfate sodium (DSS) was used to disrupt the gut barrier to determine its role in fracture healing and whether A. muciniphila still can stimulate bone fracture healing. As expected, A. muciniphila evidently improved gut barrier, reduced inflammation and restored the impaired bone healing and angiogenesis in DSS-treated mice. Our results suggest that A. muciniphila reduces intestinal permeability and alleviates inflammation, which probably induces more PDGF-BB preosteoclasts and type H vessel formation in callus, thereby promoting fracture healing. This study provides the evidence for the involvement of type H vessels in fracture healing and suggests the potential of A. muciniphila as a promising strategy for bone healing. This article has an associated First Person interview with the first author of the paper.
机译:摘要改善血运重建是骨折治疗中的主要措施之一。适度的局部炎症触发血管生成,而全身炎症阻碍血管生成。以前的研究表明,Akkermansia粘蛋白,肠道益生菌,通过收紧肠道屏障来改善全身炎症。在这项研究中,发现含有A.粘蛋白胆蛋白的颅骨小鼠比用载体处理的小鼠显示出更好的骨折愈合。值得注意的是,在2℃裂缝后粘蛋白突氏菌诱导血小板衍生的生长因子-BB(PDGF-BB)阳性的阳性的更多预胶片诱导,与血管生成和骨质发生的特异性血管亚型相结合,重合,并且可以通过PDGF-BB刺激。此外,A.粘蛋白哌菌菌治疗在早期的肠道渗透性和炎症下显着降低。葡聚糖硫酸钠钠(DSS)扰乱肠道屏障以确定其在骨折愈合中的作用,以及A.粘蛋白是否仍然可以刺激骨折愈合。正如预期的那样,A.粘蛋白哌罗显然改善了肠道屏障,降低炎症并恢复了DSS处理的小鼠中的骨愈合和血管生成受损。我们的研究结果表明,A.粘蛋白可降低肠道渗透性并减轻炎症,这可能在愈伤组织中诱导更多PDGF-BB蛋白质和型H型血管形成,从而促进骨折愈合。本研究提供了H型血管参与骨折愈合的证据,并表明A.粘蛋白作为骨愈合策略的潜力。本文有一个相关的第一人称采访本文的第一个作者。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号